ASRT earnings call for the period ending December 31, 2018.
News & Analysis: Assertio Therapeutics, Inc
The company rewarded investors with good news today.
The company announced full-year 2017 earnings yesterday after the market closed.
The company hopes a restructuring of its business can help it get back on its feet.
The company is acquiring a new drug with over $200 million in annual sales, but it won't be cheap.
These stocks helped drag the market lower. Find out why.
Here's why Fitbit, Depomed, and Twitter might benefit from a fresh set of eyes in the C-suite.
The drugmaker is reportedly drawing buyout interest from KKR & Co., upping the possibility that a sale is finally imminent.
It's painful for shareholders when M&A hopes die.
Disappointing third quarter financials is causing investors to sell off shares.